David W. Goodman, MD: Pros and Cons of Vyvanse for ADHD
Dr. David Goodman discusses the gaps in ADHD treatment.
Researchers Look at Different Treatments for Opioid Use Disorder
Researchers find 1 lipid class and 6 miRNAs differed significantly between different treatment groups.
Andrew J. Cutler, MD: Diagnosing ADHD in Pediatric Patients
It is possible to diagnose patients with ADHD as young as 2 years old.
AXS-05 Shows Promise Reducing Agitation in Alzheimer Disease
AXS-05 significantly relieved agitation, demonstrating a change from baseline in the CMAI total score of 15.4 compared to 11.5 for the placebo.
David W. Goodman, MD: ADHD Presentations at NEI
Dr. David Goodman will present 5 times during NEI about different ADHD issues and topics.
Lemborexant Helps Improve Sleep Outcomes
In the study, investigators tested the impact of the study drug in a rerandomized patient population that previously received a placebo.
Andrew J. Cutler, MD: The Impact of Screen Time on ADHD
A large portion of communication is non-verbal.
PRC-063 Helps Treat Adults with ADHD
Clinicians rated 82% of the patients receiving the study drug and 46% in the placebo group as either much improved or very much improved on the Clinical Global Impression of Improvement scale.
Andrew J. Cutler, MD: Screening Techniques for ADHD
Attempts to use neuroimaging to screen for ADHD in the past have failed.
Long-Acting Psychostimulants Improve Adolescent Drivers with ADHD
Both methylphenidate PRC-063 and lisdexamfetamine led to improved performances for drivers with ADHD.
